Vor Biopharma Quarterly Cash Flow Statement
NASDAQ: VORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.90+0.77 (+4.03%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vor Biopharma free cash flow
In the quarter ended Jun 30, 2026, Vor Biopharma generated -$25.4 million of operating cash flow and spent $120,000 on capital expenditures. That left free cash flow of -$25.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Vor Biopharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -62.81M | -219.59M | 1.72B | -812.68M | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M | -30.80M | -26.26M | -33.19M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 36.00K | 28.00K | 23.00K | 2.00K | 2.10M | 825.00K | 865.00K | 900.00K | 900.00K | 943.00K | 892.00K | 900.00K |
| Stock-Based Compensation | 9.40M | 8.87M | 7.11M | 8.03M | 1.84M | 1.93M | 1.71M | 2.26M | 2.79M | 3.08M | 1.89M | 3.16M |
| Change in Working Capital | 8.80M | -9.12M | 4.09M | 5.15M | 3.04M | -1.36M | 3.82M | 1.04M | 2.31M | -2.49M | -554.00K | 1.84M |
| Operating Cash Flow | -25.38M | -38.25M | -22.80M | -53.66M | -35.18M | -31.07M | -24.06M | -23.29M | -21.85M | -30.46M | -24.03M | -27.90M |
| Capital Expenditures | -120.00K | -48.00K | -314.00K | -244.00K | -152.00K | -231.00K | -72.00K | -34.00K | -9.00K | -114.00K | -111.00K | -465.00K |
| Investing Cash Flow | -36.53M | -263.24M | -48.97M | -244.00K | 646.00K | -230.00K | -72.00K | -34.00K | 52.99M | 43.97M | 10.34M | 40.54M |
| Financing Cash Flow | -106.00K | 74.87M | 307.80M | 21.55M | 175.06M | -606.00K | 53.29M | 41.00K | -31.00K | 96.00K | 25.00K | 176.00K |
| Net Change in Cash | -62.02M | -226.61M | 236.02M | -32.36M | 140.53M | -31.90M | 29.15M | -23.28M | 31.11M | 13.60M | -13.67M | 12.81M |
| Free Cash Flow | -25.50M | -38.29M | -23.11M | -53.91M | -35.34M | -31.30M | -24.14M | -23.32M | -21.86M | -30.58M | -24.14M | -28.36M |
This table shows 12 quarterly periods of Vor Biopharma's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VOR's reporting calendar. What is a cash flow statement?